Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 11;8(44):24913-24922.
doi: 10.1039/c8ra04389b. eCollection 2018 Jul 9.

Aromatic heterocycle galectin-1 interactions for selective single-digit nM affinity ligands

Affiliations

Aromatic heterocycle galectin-1 interactions for selective single-digit nM affinity ligands

Kristoffer Peterson et al. RSC Adv. .

Abstract

A series of 3-triazole-thiogalactosides and 3,3'-triazole-thiodigalactosides substituted with different five-membered heterocycles at the C-4 triazole position were found to have high selectivity for galectin-1. Initial studies on the 3-triazole-thiogalactosides indicated that five membered heterocycles in general gave increased affinity for galectin-1 and improved selectivity over galectin-3. The selectivity profile was similar for thiodigalactosides exemplified by 3,3' substituted thien-3-yltriazole and thiazol-2-yltriazole, both having single-digit nM galectin-1 affinity and almost 10-fold galectin-1 selectivity. The binding interactions of a thiodigalactoside based galectin-1 inhibitor with two thien-3-yltriazole moieties were studied with X-ray crystallography. One of the thiophene moieties was positioned deeper into the pocket than previously reported phenyltriazoles and formed close contacts with Val31, Ser29, Gly124, and Asp123. The affinity and structural analysis thus revealed that steric and electronic optimization of five-membered aromatic heterocycle binding in a narrow galectin-1 subsite confers high affinity and selectivity.

PubMed Disclaimer

Conflict of interest statement

F. R. Z. is an employee of and H. L. and U. J. N. are shareholders in Galecto Biotech AB, a company developing galectin inhibitors. The other authors have no conflicts to declare.

Figures

Fig. 1
Fig. 1. Thien-3-yl thiodigalactoside derivative 1 with high affinity for galectin-1.
Scheme 1
Scheme 1. Synthesis of triazoles 4–9 and 12–15. Reagents and conditions: (a) NaOMe, MeOH, rt; (b) alkyne, CuI, DIPEA, MeCN, 50 °C; (c) (i). 1-{[2-(Trimethylsilyl)ethoxy]methyl}-4-[2-(trimethylsilyl)ethynyl]-1H-imidazole, CuI, DIPEA, MeCN, 50 °C; (ii). BF3OEt2, CH2Cl2, rt; (d) methyl thioglycolate, BF3 OEt2, CH2Cl2, rt; (e) (i). Alkyne, CuI, DIPEA, MeCN, 50 °C; (ii). NaOMe, MeOH, rt; (iii). LiOH, THF : H2O (9 : 1), rt. Tol = p-methylphenyl.
Scheme 2
Scheme 2. Synthesis of thiodigalactosides 19–20 and 22–23. Reagents and conditions: (a) (i). alkyne (3 equiv.), CuI, DIPEA, DMF, 50 °C; (ii). NaOMe, MeOH, rt; (b) (i). Thiazol-2-ylethynyltrimethylsilane (1.5 equiv.), CuI, DIPEA, DMF, 50 °C; (ii). NaOMe, MeOH, rt; (c) alkyne, CuI, DIPEA, DMF, 50 °C.
Scheme 3
Scheme 3. Synthesis of fluorescent probe 25. Reagents and conditions: (a) 1,3-propanedithiol, Et3N, MeOH, rt; (b) 5-FAM-NHS, DIPEA, DMSO, rt.
Fig. 2
Fig. 2. Difference electron density of 1 in the galectin-1 binding site. Difference electron density calculated from refinement with the ligand (stick representation) omitted from the model (|Fo| − |Fc| αcalc; grey mesh, contoured at 3σ) and the protein represented by a grey solvent-accessible surface. The narrow pocket accommodating one of the thiophene rings is indicated with a yellow arrow.
Fig. 3
Fig. 3. Galectin-1 binding site interactions with 1. H-bond interactions between ligand (carbons white) and protein/water (carbons green) are shown as dashed lines.
Fig. 4
Fig. 4. Comparison of the binding conformation of 1 when bound to galectin-1 (carbons pink) and galectin-3  (carbons green).

Similar articles

Cited by

References

    1. Barondes S. H. Castronovo V. Cooper D. N. W. Cummings R. D. Drickamer K. Felzi T. Gitt M. A. Hirabayashi J. Hughes C. Kasai K. Leffler H. Liu F.-T. Lotan R. Mercurio A. M. Monsigny M. Pillai S. Poirer F. Raz A. Rigby P. W. J. Rini J. M. Wang J. L. Cell. 1994;76:597–598. doi: 10.1016/0092-8674(94)90498-7. - DOI - PubMed
    1. Leffler H. Carlsson S. Hedlund M. Qian Y. Poirier F. Glycoconjugate J. 2002;19:433–440. doi: 10.1023/B:GLYC.0000014072.34840.04. - DOI - PubMed
    1. Astorgues-Xerri L. Riveiro M. E. Tijeras-Raballand A. Serova M. Neuzillet C. Albert S. Raymond E. Faivre S. Cancer Treat. Rev. 2014;40:307–319. doi: 10.1016/j.ctrv.2013.07.007. - DOI - PubMed
    1. van Beijnum J. R. Thijssen V. L. Läppchen T. Wong T. J. Verel I. Engbersen M. Schulkens I. A. Rossin R. Grüll H. Griffioen A. W. Nowak-Sliwinska P. Int. J. Cancer. 2016;139:824–835. doi: 10.1002/ijc.30131. - DOI - PubMed
    1. Blanchard H. Bum-Erdene K. Buhari M. H. Xing Y. Expert Opin. Ther. Pat. 2016;26:537–554. doi: 10.1517/13543776.2016.1163338. - DOI - PubMed